<DOC>
	<DOCNO>NCT01964573</DOCNO>
	<brief_summary>The objective trial investigate PK ( Pharmacokinetic ) repeated-dose application Rotigotine transdermal patch healthy young male female Korean subject submit MFDS new drug application approval .</brief_summary>
	<brief_title>Trial Evaluate Pharmacokinetics , Safety , Tolerability Rotigotine Healthy Korean Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject male female age 19 45 year age ( inclusive ) Subject healthy ( clinically relevant finding investigation preexamination ) judge investigator Subject normal body weight determine Body Mass Index ( BMI ) 18 28 kg / m² Subject Korean ( parent pure Korean ) Subject history drug alcohol abuse within last 2 year Subject history transient ischemic attack stroke within last 12 month Subject history current condition Epilepsy / seizures Subject history significant skin hypersensitivity adhesives transdermal product recently unsolved Contact Dermatitis Subject history present condition Atopic Eczematous Dermatitis , Psoriasis , / active skin disease Female subject pregnant lactating Subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's ability participate trial Subject QTcB ( accord Bazett´s formula ) interval ≥ 450 ms female ≥ 430 ms male clinically relevant Electrocardiogram ( ECG ) find Subject clinically relevant abnormality physical examination , clinically relevant deviation normal range clinical chemistry , hematology , urinalysis Subject relevant hepatic dysfunction ( total Bilirubin &gt; 2 mg /dL Alanine Aminotransferase [ ALT ] Aspartate Aminotransferase [ AST ] great 2 time upper limit normal reference range ) Subject positive test Human Immunodeficiency Virus antibody ( HIV ) 1/2Ab , Hepatitis B surface Antigen ( HBsAg ) Hepatitis C Virus Antibody ( HCVAb ) Subject positive test alcohol drug Subject consume 150 g alcohol / week Subject make blood donation comparable blood loss ( &gt; 400 ml ) within last 3 month Subject smoke 5 cigarette per day do within previous 6 month Subject clinically relevant allergy Subject take medication ( exclude oral hormonal contraceptive ) currently within 2 week prior first day dose ( exception Acetaminophen [ 1000 mg per day per o ] may take 48 hour prior commencement dose ) Female subject currently take oral hormonal contraceptive le 2 month Subject symptomatic orthostatic hypotension decrease Blood Pressure ( BP ) supine stand position ≥ 20 mmHg systolic BP ≥ 10 mmHg diastolic BP 1 / 3 minute Subject pulse rate rest le 45 beat per minute 100 beat per minute ( measure supine position ) Subject systolic Blood Pressure ( BP ) low 100 mmHg high 150 mmHg diastolic BP high 95 mmHg ( measure supine position ) Subject current history clinically relevant motor disturbance , impairment memory , sleep disturbance neurodegenerative disease ( e.g . , Alzheimer Dementia , Diffuse , Lewy Body Dementia , Amyotrophic Lateral Sclerosis [ ALS ] , Multiple Sclerosis ) Subject take herbal medicine therapy within last 2 week Subject consumes 3 cup ( 450 ml ) caffeinated beverage per day within last 2 week</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Rotigotine</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy subject</keyword>
</DOC>